

the removal of Column F for “Discretionary Disaster Relief Funds Construction and Major Renovation Grant Document Number CCDY” which is a program not funded by ACF; the renaming of line 13a “total federal unliquidated” to “total federal obligations (not yet liquidated) (excluding construction/major renovation” to clarify what amount should be reported on this line; the addition of line 13b. “total federal obligations Into yet liquidated) for construction/major renovation” to distinguish between CCDF activities and activities for the construction or major renovation of CCDF projects; the removal of line 14(a) “was the tribal lead agency unable to obligate at least

50% of the CCDF stabilization grants by December 11, 2021?” because this question relates to a subaccount for a program set to close by 9/30/2024; and the removal of the reallocated funds selection for COVID supplemental funds since the deadline to request reallocated funds for these subaccount awards is in the past. The instructions for this form were updated to account for the described changes, to clarify existing instructions, and to update language to reflect current Office of Child Care and Office of Grants Management policies and program instruction to recipients.
 • *Child Support Services Program Financial Reporting Forms (OCSS–34 and OCSS–396)*: The title of these forms was updated to reflect the change in

name of the program office from the Office of Child Support Enforcement to the Office of Child Support Services. References to the name within the forms and instructions were also updated.

Respondents: ACF-funded non-discretionary grant programs.

Annual Burden Estimates

Find currently approved information collections here: https://www.reginfo.gov/public/do/PRAICList?ref_nbr=202308-0970-008. The request to OMB will include an extension request for the following approved collections.

Burden Estimates—Ongoing Requests

Study	Number of respondents	Number of responses per respondent	Average burden hours per response	Annual burden hours
Child Care and Development Fund (CCDF) ACF–696 Financial Report for States and Territories	56	4	5	1,344
Child Care and Development Fund (CCDF) ACF–696T Financial Report for Tribal Grantees	221	1	7	1,547
Child Support Services Program Financial Reporting Forms (OCSS–34 and OCSS–396)	168	4	14	9,408
Form CB–496: Title IV–E Programs Quarterly Financial Report	67	4	25	6,700
Refugee Cash and Medical Assistance Federal Financial Report (ORR–2) Supplemental Data Collection	66	1	1.67	110
Refugee Support Services Federal Financial Report (SF–425) Supplemental Data Collection	53	4	4	848
Totals:	768	Avg: 2.7	Avg: 8.9	19,957

Burden Estimates—New Requests

Based on use of this generic, we have revised burden estimates for the next 3 years.

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Burden hours
Non-discretionary Grant Financial Reports	700	4	12	33,600

Mary C. Jones,
ACF/OPRE Certifying Officer.
 [FR Doc. 2024–09879 Filed 5–6–24; 8:45 am]
BILLING CODE 4184–88–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Statement of Organization, Functions, and Delegations of Authority

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration’s (FDA), Center for Devices and Radiological Health’s (CDRH), Office of Communication and Education (OCE) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on December 21, 2023, and it became effective on January 22, 2024.

FOR FURTHER INFORMATION CONTACT: Yashika Rahaman, Director, Office of Planning, Evaluation and Risk Management, Office of Finance, Budget, Acquisitions and Planning, Food and Drug Administration, 4041 Powder Mill

Rd., Beltsville, MD 20705–4304, 301–796–3843.

I. Introduction

Part D, Chapter D–B, (Food and Drug Administration), the Statement of Organization, Functions and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, 60 FR 56606, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112, August 30, 2007, 74 FR 41713, August 18, 2009, 76 FR 45270, July 28, 2011, and 84 FR 22854, May 20, 2019) is amended to reflect the reorganization of the CDRH OCE.

The reorganization retitled OCE as the Office of Communication, Information Disclosure, Training, and Education (OCITE); abolished the Digital Communication Media Staff; established the Office of Communication and Content Development (OCCD) and the Office of Training and Education (OTE) within OCITE, established the Division of Digital Communication and Marketing (DDCM) within OCCD, and realigned the existing divisions to the new offices.

DCCE. ORGANIZATION. CDRH's OCITE is headed by the Director, and includes the following:

Office of Communication, Information Disclosure, Training, and Education (DCCE)

Program Management Operations Staff (DCCE1)

Office of Communication and Content Development (DCCEE)

Division of Communication (DCCEEA)

Division of Information Disclosure (DCCEEB)

Division of Digital Communication and Marketing (DCCEEC)

Office of Training and Education (DCCEF)

Division of Employee Training and Development (DCCEFA)

Division of Industry and Consumer Education (DCCEFB)

II. Delegations of Authority

Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.

III. Electronic Access

This reorganization is reflected in FDA's Staff Manual Guide (SMG). Persons interested in seeing the complete SMG can find it on FDA's website at: <https://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm>.

(Authority: 44 U.S.C. 3101).

Xavier Becerra,

Secretary, Department of Health and Human Services.

[FR Doc. 2024-09381 Filed 5-6-24; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Statement of Organization, Functions, and Delegations of Authority

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration's (FDA), Center for Devices and Radiological Health's (CDRH), Office of Product Evaluation and Quality (OPEQ) has modified their organizational structure. The new organizational structure was approved by the Secretary of Health and Human Services on December 21, 2023, and it became effective on January 22, 2024.

FOR FURTHER INFORMATION CONTACT: Yashika Rahaman, Director, Office of Planning, Evaluation and Risk Management, Office of Finance, Budget, Acquisitions and Planning, Food and Drug Administration, 4041 Powder Mill Rd., Beltsville, MD 20705-4304, 301-796-3843.

I. Introduction

Part D, Chapter D-B, (Food and Drug Administration), the Statement of Organization, Functions and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, 60 FR 56606, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112, August 30, 2007, 74 FR 41713, August 18, 2009, 76 FR 45270, July 28, 2011, and 84 FR 22854, May 20, 2019) is amended to reflect the reorganization of the CDRH OCE.

The reorganization of OPEQ impacted the OPEQ's Office of Clinical Evidence and Analysis (OCEA) and the OPEQ's Office of Health Technology IV (OHT IV). OCEA established the Division of Clinical Evidence and Analysis IV and the Division of Clinical Evidence and Analysis V. OHT IV established the Division of Health Technology IV C.

DCCFB. ORGANIZATION. CDRH's OPEQ OCEA is headed by the Director, and includes the following:

Office of Clinical Evidence and Analysis (DCCFB)

Division of Clinical Evidence and Analysis I (DCCFBA)

Division of Clinical Evidence and Analysis II (DCCFBB)

Division of Clinical Evidence and Analysis III (DCCFBC)

Division of Clinical Evidence and Analysis IV (DCCFBD)

Division of Clinical Evidence and Analysis V (DCCFBE)

DCCFF. ORGANIZATION. CDRH's OPEQ OHT IV is headed by the Director, and includes the following:

Office of Health Technology IV (DCCFF) Division of Health Technology IV A (DCCFFA)

Division of Health Technology IV B (DCCFFB)

Division of Health Technology IV C (DCCFFC)

II. Delegations of Authority

Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.

III. Electronic Access

This reorganization is reflected in FDA's Staff Manual Guide (SMG). Persons interested in seeing the complete SMG can find it on FDA's website at: <https://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm>.

(Authority: 44 U.S.C. 3101).

Xavier Becerra,

Secretary, Department of Health and Human Services.

[FR Doc. 2024-09382 Filed 5-6-24; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2024-N-1917]

Fresenius Kabi USA, LLC, et. al.; Withdrawal of Approval of 12 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES: Approval is withdrawn as of June 6, 2024.

FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New